Shree Ganesh Remedies LtdQ3 FY24Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Ltd

Q3 FY24 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→Revenue growth is expected driven by increasing CRAMS (Contract Research and Manufacturing Services) projects, with trial quantities being supplied and ramp-up over multiple quarters.
→Peak volumes for CRAMS projects are anticipated 1.5 to 2 years down the line, indicating gradual scale-up.
→New blocks (9,10,11) at Ankleshwar planned but will be commissioned based on confirmed projects; gross block addition estimated at Rs. 50-80 crores.
→Dahej site expansion is planned for commercial-scale production once supply contracts are signed; construction expected to take 15-18 months after groundwork.
→European market demand has been dampened recently but expected to stabilize with increased inquiries from multiple geographies including Europe, Japan, and USA.
→Specialty chemicals and fine chemicals segments are showing promise with new inquiries and potential supplier upgrades.
→Long-term projects indicate stable revenue streams 2-3 years ahead.
→Overall margin guidance is 24-28% EBITDA, with higher margins in early CRAMS phases balancing out over time.

Category 3

→Growth expected to continue driven by strategic focus on product mix optimization and profitability enhancement (Page 4).
→Commercial supply for CRAMS projects ramping up over multiple quarters; peak volumes expected 1.5 to 2 years down the line (Pages 13-15).
→New blocks (9, 10, 11) and Dahej site expansions planned, contingent on project contracts, indicating capacity for future scale (Pages 13-14).
→EBITDA margins anticipated to normalize in the 24-28% range over the medium term; peak margin of 30%+ seen recently considered aberration due to initial CRAMS projects (Page 11).
→Revenue contribution from CRAMS projects expected to increase gradually but cautiously disclosed due to competitive reasons (Page 15).
→Backward integration efforts aimed at maintaining healthy margins amid volume-driven pricing pressure (Page 7).
→Overall, a steady revenue and margin growth trajectory is anticipated over 3-5 years with ongoing project commercialization and capacity expansion.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Shree Ganesh Remedies Ltd and 1,400+ other companies.

→The transcript from the Q2FY25 earnings call of Shree Ganesh Remedies Limited does not mention any current or planned fundraising through debt or equity.
→No specific comments were made about raising capital for ongoing or future projects.
→Capex plans for expansion (blocks 9, 10, 11 at Ankleshwar and new blocks at Dahej) are contingent on project approvals and customer contracts but no financing details were discussed.
→The company is focusing on phased project developments, backed by existing resources and project-specific investments rather than broad fundraising.
→Management emphasizes organic growth and capacity expansion based on customer demand without indicating external equity or debt issuance.

→Currently engaged in multiple CRAMS projects with some commercialized, including one started in Q4 of last year.
→Trial quantities for ongoing CRAMS projects expected around Q2 of next financial year.
→Major revenue and volume ramp-up from these projects anticipated 1.5 to 2 years down the line.
→Customer is conducting market studies to clarify peak volume; clearer visibility expected by Q4 FY25.
→Additional CRAMS projects are in pipeline, with sample approvals and R&D ongoing.
→No specific orderbook numbers disclosed due to competitive reasons and NDAs.
→Blocks 9, 10, and 11 expansions planned post-project confirmation; gross block investment estimated between Rs. 50-80 crores.
→Dahej site expansion contingent upon signed supply contracts for high-volume projects; commercial production expected after 1.5-2 years of sample approvals and construction.

Yes

→Blocks 9, 10, and 11 at Ankleshwar will be commissioned and designed only when specific projects or chemistry requirements arise; typical Capex per block ranges between ₹10-20 crore, totaling ₹50-80 crore for the three blocks.
→Block 7 at Dahej is being finalized; construction usually takes 15-18 months post-approval.
→Dahej site is planned for large-scale, dedicated customer projects with major Capex starting 1.5 to 2 years from now after signing supply contracts.
→Current capacity expansions at Ankleshwar and ongoing efforts aim to support scale-up and sample submissions before major Dahej investments.
→The company employs a project-driven Capex approach, building capacity aligned with customer demand and technology.
→Block 8 has started commercial operations from Q1 FY25 and is expected to contribute meaningfully soon.
→Innovation efforts include backward integration and technology improvements to maintain margins and production efficiency.

How does Shree Ganesh Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Shree Ganesh Remedies Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Shree Ganesh Remedies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.